RECEIVED
CENTRAL FAX CENTER

SERIAL NO.:

APPLICANT(S): LEWKOWICZ, Shlomo et al.

FILED:

10/536,982 May 31, 2005

Page 2

OCT 1 5 2007

AMENDMENTS TO THE CLAIMS

Please amend claim 88 as follows.

The following listing of claims replaces all versions, and listings, of claims in this application.

Listing of Claims:

1-72. (Canceled)

- 73. (Previously Presented) The method according to claim 88 comprising imaging the interaction chamber with an optical system.
- 74. (Previously Presented) The method according to claim 88 comprising imaging the optical changes in the interaction chamber.
- 75. (Previously Presented) The method according to claim 88 comprising illuminating said interaction chamber wherein at least a portion of the interaction chamber is transparent in a wavelength of illumination.
- 76. (Previously Presented) The method according to claim 88, comprising transmitting images to an external receiver.
- 77. (Previously Presented) The method according to claim 88, comprising pumping the endoluminal sample into the interaction chamber.
- 78. (Withdrawn) An in-vivo imaging device for determining an in vivo condition, the imaging device comprising:

an interaction chamber comprising first and second openings, wherein the first opening is to allow an endo-luminal sample to enter and the second opening is to discharge the endoluminal sample;

an imager for capturing an image of at least the interaction chamber, wherein the interaction chamber and the imager are positioned behind an optical window.

79. (Withdrawn) The in-vivo imaging device according to claim 78 wherein the interaction chamber includes a capillary.

APPLICANT(S): LEWKOWICZ, Shlomo et al.

SERIAL NO.:

10/536,982 May 31, 2005

FILED: Page 3

80. (Withdrawn) The in-vivo imaging device according to claim 78 wherein the interaction chamber is etched into a slab of glass.

- 81. (Withdrawn) The in-vivo imaging device according to claim 78 wherein the interaction chamber includes an indicator configured to react with the endo-luminal sample.
- 82. (Withdrawn) The in-vivo imaging device according to claim 81, comprising first and second membranes configured to restrict the indicator to the interaction chamber.
- 83. (Withdrawn) The in-vivo imaging device according to claim 78, comprising first and second membranes configured to selectively enable passage of the endo-luminal sample.
- 84. (Withdrawn) The in-vivo imaging device according to claim 78, comprising an optical system.
- 85. (Withdrawn) The in-vivo imaging device according to claim 78 comprising a transmitter to transmit the captured image to an external receiving system.
- 86. (Withdrawn) The in-vivo imaging device according to claim 78, wherein the imager is configured for capturing an image of the interaction chamber and a gastrointestinal tract wall.
- 87. (Withdrawn) The in-vivo imaging device according to claim 78 comprising an illumination source configured to illuminate the interaction chamber.
- 88. (Currently Amended) A method for determining body lumen conditions in-vivo, the method comprising:

allowing a first endo-luminal sample to enter through a first opening of an in-vivo interaction chamber, a first endo luminal sample, the interaction chamber including having immobilized therein an indicator configured to react with at least the first endo-luminal sample, said reaction occurring within the interaction chamber, and the reaction resulting in an optical change;

detecting the optical change;

discharging the first endo-luminal sample through a second opening of the interaction chamber; and

replacing the first sample in the interaction chamber with a new sample.

APPLICANT(S): LEWKOWICZ, Shlomo et al.

SERIAL NO.: FILED:

10/536,982 May 31, 2005

Page 4

89. (Previously Presented) The method according to claim 88 comprising capturing an image of a gastrointestinal wall.